Refeeding in Post-ERCP Pancreatitis

Timing of Oral Refeeding in Post-ERCP Pancreatitis

Endoscopic retrograde cholangio-pancreatography (ERCP) is the most commonly used technique for diagnosis and treatment in the treatment of bile duct diseases including bile duct cholelithiasis and malignant/benign biliary obstruction. In particular, ERCP is an essential procedure for the removal of bile duct gallstones and bile drainage in malignant/benign biliary obstruction patients.

Among ERCP-related complications, especially "post-ERCP pancreatitis (PEP)", which occurs due to the anatomical structure of the pancreatic biliary system, statistically occurs in about 5-10% of patients who first received ERCP. It is known, and treatment for PEP is the same as treatment for general acute pancreatitis but is known to have a relatively worse prognosis.

The basis of treatment for acute pancreatitis is a conservative treatment based on fasting and fluid treatment, and starting oral diet after abdominal pain and pancreatic enzyme levels (amylase/lipase) normalized. However, a recent study reported that early oral diet could improve the patient's prognosis. According to a systematic review of 11 randomized trial papers by Valerie et al., it was reported that the early diet had the effect of reducing hospital stay without increasing adverse events when comparing the prognosis of the early refeeding group and delayed refeeding group. This result is theoretically considered to be because the oral diet has the advantage of increasing intestinal permeability, gut motility and reducing the likelihood of pancreatic necrosis/ infection compared to the parenteral diet.

As above, PEP has the same treatment method as general acute pancreatitis but is known to have a relatively worse prognosis. However, the effect of an early diet recently attempted in acute pancreatitis has not been reported in patients with PEP. Therefore, we investigate the effects of early and delayed diets on the prognosis of patients with PEP through a prospective multicenter study.

Study Overview

• Status: Recruiting
• Conditions: Post-ERCP Pancreatitis
• Intervention / Treatment: Other: early refeeding; Other: delayed refeeding

Detailed Description

1. Selection of research subjects A total of 80 patients, who have occurred pancreatitis after ERCP, will be enrolled at Yonsei University Sinchon Severance Hospital, Seoul National University Hospital, Dongguk University Ilsan Hospital, Gachon University Gil Hospital, Gyeongsang National University Changwon Hospital, Kyungpook National University Hospital, Seoul St. Mary's Hospital, Korea University Ansan Hospital, Pusan National University Hospital. The purpose and contents of this clinical trial are informed in detail to the subject and consent is obtained.
2. Evaluation of eligibility Eligibility is determined based on the basic patient data including physical examination, vital signs, body measurements, medical history, concomitant drugs, laboratory tests, and other basic examinations made at the first visit.
3. Grouping and randomization After ERCP was performed, the study subjects who were judged to have PEP according to enroll criteria were divided into early and delayed refeeding groups using a random number table and assigned 1:1 to proceed with the study.

4. Timing of refeeding In the early refeeding group, oral diet is started 24 hours after PEP is confirmed.

   In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.

5. Interruption of refeeding In both early and delayed refeeding groups, the oral diet is stopped when the pain scale the patient complains after starting oral diet increases to VAS 5 points or more, or the patient refuses to eat due to abdominal pain or other reasons. The diet is restarted after the amylase/lipase level decreases below the upper normal limit, the patient's pain has disappeared, and the bowel movement is restored.

6. Dropout criteria

   1. In the case of delayed diet group when symptoms persist for more than 96 hours and cannot start a diet
   2. When fasting is necessary for other reason, such as an imaging test or endoscopy
   3. When it is determined that a parenteral diet is necessary for reasons such as difficulty swallowing
   4. When the researcher judged that the clinical trial cannot be continued
7. Discharge criteria and hospitalization period for PEP If the patient is tolerable for more than 24 hours after the soft diet (abdominal pain improvement, lab amylase/lipase level decreases to less than 2 times the upper normal limit, it is judged that PEP has improved and the discharge criteria have been satisfied. From the point of diagnosis of PEP to the point of time when the discharge criteria are satisfied is defined as the "hospitalization period for PEP".

• Study Type: Interventional
• Enrollment (Anticipated): 80
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jung Hyun Jo; Phone Number: +82-2-2228-2274; Email: junghyunjo83@yuhs.ac

Study Locations

• Korea, Republic of
  • Ansan-si, Korea, Republic of
    • Recruiting
    • Korea University Ansan Hospital
    • Contact: Jung Wan Choe
  • Busan, Korea, Republic of
    • Recruiting
    • Pusan National University Hospital
    • Contact: Sung Yong Han
  • Changwon, Korea, Republic of
    • Recruiting
    • Gyeongsang National University Changwon Hospital
    • Contact: Jae Min Lee
  • Daegu, Korea, Republic of
    • Recruiting
    • Kyungpook National University School of Medicine
    • Contact: Dong Kee Jang
  • Incheon, Korea, Republic of
    • Recruiting
    • Gachon University College of Medicine
    • Contact: Eui Joo Kim
  • Seoul, Korea, Republic of, 03722
    • Recruiting
    • Yonsei University College of Medicine
    • Contact: JUNGHYUN JO; Phone Number: +82-2-2228-2274; Email: junghyunjo83@yuhs.ac
  • Seoul, Korea, Republic of
    • Recruiting
    • Seoul National University Hospital
    • Contact: Sang Hyub Lee
  • Seoul, Korea, Republic of
    • Recruiting
    • Seoul st. mary's hospital
    • Contact: Young Hoon Choi
  • Seoul, Korea, Republic of
    • Recruiting
    • Seoul Metropolitan Government Boramae Medical Center
    • Contact: Dong Kee Jang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 78 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients aged 20 to 80

2. As patients who developed pancreatitis after receiving ERCP, the following must be satisfied at the same time.

   1. increased serum amylase or lipase 3 times higher than the normal range, at 4 hours after ERCP or the morning of the following day,
   2. New or worsening abdominal pain compatible with pancreatitis, arising 4 hours after ERCP or the next morning

Exclusion Criteria:

1. If the intended procedure is not completed
2. If complications such as abdominal perforation or bleeding have occurred or are suspected
3. If it is judged as severe acute pancreatitis with multi-organ failure la.
4. When PEP has occurred, but additional imaging tests and endoscopy for diagnosis of the underlying disease or treatment of complications of the patient are required, and fasting is necessary regardless of this study
5. Patients with a history of chronic pancreatitis
6. Pregnant women, lactating women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: early refeeding group; In the early refeeding group, oral diet is started 24 hours after PEP is confirmed.	Other: early refeeding; In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
Active Comparator: delayed refeeding group; In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2.	Other: delayed refeeding; In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
hospitalization period for PEP	If the patient is tolerable for more than 24 hours after the soft diet (abdominal pain improvement, lab amylase/lipase level decreases to less than 2 times the upper normal limit, it is judged that PEP has improved and the discharge criteria have been satisfied. From the point of diagnosis of PEP to the point of time when the discharge criteria are satisfied is defined as the "hospitalization period for PEP".	up to 1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of acute severe pancreatitis	comparing rate of incidence of severe acute pancreatitis	up to 1 month
readmission rate (<30 days)	comparing readmission rate of each group until 30 days after discharge	up to 1 month
mortality rate	comparing mortality rat of each group during hospitalization	up to 1 month
complication rate	comparing complication rate including nausea/vomiting, recurrent abdominal pain, necrotizing pancreatitis of each group during hospitalization	up to 1 month

Collaborators and Investigators

• Sponsor: Yonsei University
• Investigators: Principal Investigator: Jung Hyun Jo, Severance Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 18, 2021
• Primary Completion (Anticipated): November 10, 2022
• Study Completion (Anticipated): December 30, 2022

Study Registration Dates

• First Submitted: February 7, 2021
• First Submitted That Met QC Criteria: February 9, 2021
• First Posted (Actual): February 11, 2021

Study Record Updates

• Last Update Posted (Actual): October 26, 2022
• Last Update Submitted That Met QC Criteria: October 24, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pancreatic Diseases; Pancreatitis
• Other Study ID Numbers: 4-2020-1237

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No